TaiGen Forms $102 Million Hepatitis C JV with YiChang HEC Pharma

TaiGen Biotech formed a $102 million JV with YiChang HEC ChangJiang Pharma to develop a dual-drug, oral direct-acting antiviral treatment for chronic hepatitis C. Each company will contribute their clinical stage antivirals to the Taiwan-China JV, a first cross-straits JV according to the companies. TaiGen will put in China rights to furaprevir (TG-2349) for a 49% stake in the JV. HEC will transfer China rights for yimitasvir (DAG-181), plus an undisclosed amount of cash, to the JV for 51% ownership. More details.... Stock Symbols: (TWO: 4157) (HK: 1558) Share this with colleagues: // //